Phase 4 N=77 Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis
Chronic Rhinosinusitis
Primary: Mean Reduction in SNOT-20 Scores — 1.8; 5.5 units on a scale — p=0.23
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=374 BAY12-8039: 5 Days for Sinusitis vs Placebo
Sinusitis
Primary: Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT)) — 78.1; 66.7; 19.2; 33.3 Percentage of subjects — p=0.189
N/A N=98 Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children
Sinusitis
Primary: Proportion of Children With Clinical Relapse on Day 10 (Short Course) vs Day 20 (Long Course) — 13; 8; 9; 10 Participants
Phase 1 N=16 Potential for Cortisol Suppression With the Use of High Volume Nasal Mometasone Irrigations in Varying Dosages.
Chronic Rhinosinusitis (Diagnosis)
Primary: Morning "AM" Serum Cortisol Level — 17.35; 14.48 mcg/dL
N/A N=40 Comparing the Use of Saline or Saline Plus Gentamycin in Nasal Irrigation to Treat Chronic Sinusitis in Children
Sinusitis
Primary: Change in Computed Tomography (CT) Score After Treatment — -.64; -.63; -.5; -.5 units on a scale
Phase 4 N=40 Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis
Sinusitis
Primary: Number of Patients Recommended for Sinus Surgery After 3 Weeks of Antibiotic Therapy — 7; 8; 0; 6 Participants
Phase 3 N=50 Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)
Chronic Sinusitis · Nasal Polyposis
Primary: Number of Participants With Implant-Related Serious Adverse Events — 0 Participants
Phase 3 N=105 A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis
Chronic Sinusitis
Primary: Percentage of Sinuses Requiring Post-operative Intervention — 33.3; 46.9 percentage of sinuses — p=0.0280
Phase 3 N=705 Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
Chronic Sinusitis With or Without Nasal Polyps
Primary: Adverse Events — 270 participants
Phase 2 N=20 Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Primary: Ratio to Baseline in Peripheral Blood Eosinophil Counts After 6 Months of Treatment — 0.06 ratio to baseline — p=< 0.001
N/A N=50 Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis
Chronic Sinusitis
Primary: Safety as Determined by the Frequency of Serious Adverse Local Tissue Response (SALT) — 6 Number of Sinuses
Phase 3 N=300 S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps
Chronic Sinusitis · Nasal Polyposis
Primary: Nasal Obstruction/Congestion Score — 2.36; 2.35; 1.56; 1.79 units on a scale — p=0.0074
Phase 2 N=71 LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)
Chronic Sinusitis · Chronic Rhinosinusitis (Diagnosis)
Primary: Change From Baseline (CFBL) in Chronic Sinusitis Symptom Scores at Week 4 — -2.24; -2.65; -2.28 score on a scale
Phase 4 N=49 Sinuclean's Treatment Of Sinusitis' Symptoms
Sinusitis
Primary: Presence of Mucus in the Paranasal Sinuses (Outcome Measure Percentage of Patients) — 71; 57; 33 percentage of patients — p=<0.05
Phase 2 N=16 Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
Sinusitis · Cystic Fibrosis
Primary: Computed Tomography Evidence of Less Sinus Disease — 5.875; 3 units on a scale — p=0.2